secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001193125-25-189109
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx discontinues AMX0035 program for PSP after Phase 2b miss
---------------------------------------------------------------

- AMX0035 failed to show differences vs placebo on primary or secondary outcomes at Week 24.
- Company will discontinue Phase 2b trial and open-label extension; will not proceed to Phase 3.
- Safety data consistent with prior AMX0035 studies.
- ORION program for progressive supranuclear palsy (PSP) is discontinued entirely.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525189109/0001193125-25-189109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525189109/d23231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-189109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer